ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Personalized Antibiogram: A Novel Multitask Machine Learning Framework for Simultaneous Prediction of Antimicrobial Resistance Profile With Enhanced Detection of Carbapenem Resistance in Enterobacteriaceae.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence for infection surveillance, risk stratification, and antimicrobial decision support in acute-care hospitals: a scoping review.Frontiers in artificial intelligence · 2026Pooled it
- Co-Resistance Structure and Multidrug Resistance-Associated Antimicrobials inAntibiotics (Basel, Switzerland) · 2026Article
- Machine learning-based prediction of meniscal tears in ACL reconstruction using BMI, time to surgery, injury mechanism, and Tegner activity score: A temporally validated decision tool.Journal of experimental orthopaedics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundConventional hospital antibiograms summarize aggregated resistance rates, limiting their utility for individualized antimicrobial selection. Existing statistical and machine learning models predict each phenotype separately, ignoring correlations among resistance profiles. We developed novel multitask extreme gradient boosting (XGBoost) models utilizing structured data in electronic health records (EHRs) to predict resistance to 8 antimicrobial classes simultaneously and evaluated their performance within the Veterans Health Administration (VHA).
methodsWe conducted a retrospective multicenter study of Escherichia coli and Klebsiella spp. isolates collected at 127 hospitals and >1400 clinics from January 2017 to September 2024. Data from January 2017 to September 2023 were used for model development, while data from October 2023 to September 2024 were used for simulated prospective testing. Model performances were compared to hospital antibiograms and single-target XGBoost models.
resultsThe training cohort included 536 252 E. coli and 246 898 Klebsiella spp. isolates; the test cohort included 75 138 and 38 015 isolates, respectively. On the test data, the multitask model achieved overall areas under the receiver operating characteristic curve (AUROCs) of 0.779 (E. coli) and 0.810 (Klebsiella spp.), with good to excellent per-class performance (AUROC range, 0.743-0.847). A multitask approach improved calibration and decreased false-negative rates for carbapenem resistance while predicting individualized resistance probabilities for all target antimicrobials simultaneously ("personalized antibiograms").
conclusionsA multitask XGBoost framework can accurately predict individualized resistance profiles for common Gram-negative pathogens, outperforming conventional antibiograms and single-target models. Personalized antibiograms may enhance the selection of empiric therapy, including the detection of carbapenem resistance in low-endemicity settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.